{"pageContent": "Context: Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T treatment extends survival but is independent of traditional short-term markers of treatment response observed with chemotherapy and contemporary hormonal treatments. Therefore, it is essential that clinicians understand the mechanism of action of sipuleucel-T and how this can translate in the clinic.", "metaData": {"source": "Erectile dysfunction and urinary incontinence after prostate cancer treatment\nhttps://pubmed.ncbi.nlm.nih.gov/22018407/"}}